Brian Druker
Papers
1
Total Citations
2
H-Index
1
About
Dr. Brian Druker is a pioneering oncologist and translational researcher whose work has fundamentally transformed the treatment of chronic myeloid leukemia (CML). His key research areas include targeted cancer therapies, tyrosine kinase inhibition, and precision medicine in hematologic malignancies. Dr. Druker’s landmark contributions center on the clinical development of imatinib (Gleevec), the first molecularly targeted therapy to successfully inhibit the BCR-ABL fusion protein responsible for CML. This breakthrough turned a once-fatal disease into a manageable chronic condition, with imatinib achieving unprecedented five-year survival rates exceeding 90%. His work has been cited over 50,000 times, reflecting its profound impact on oncology. Among his notable achievements, Dr. Druker has received the Lasker-DeBakey Clinical Medical Research Award and the Japan Prize, and he serves as director of the Knight Cancer Institute at Oregon Health & Science University. His research continues to explore drug resistance mechanisms and novel therapies for acute leukemias, including rare subtypes like TCF3-HLF rearranged ALL, demonstrating his enduring commitment to advancing targeted treatments for the most challenging cancers.
Research Focus
Key Achievements
Top Papers
- 1